Views
1 year ago

Educational Book - ASCO Annual Meeting - American Society of ...

Educational Book - ASCO Annual Meeting - American Society of ...

Educational Book - ASCO Annual Meeting - American Society of

AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2013 EDUCATIONAL BOOK “Building Bridges to Conquer Cancer” 49th Annual Meeting | May 31-June 4, 2013 | Chicago, Illinois | Volume 33

  • Page 2 and 3: American Society of Clinical Oncolo
  • Page 5 and 6: Contents 2013 ASCO Annual Meeting D
  • Page 7 and 8: Soy Isoflavones and Breast Cancer A
  • Page 9 and 10: Raising the Bar: Can We Diminish th
  • Page 11 and 12: Pathways in Gynecologic Malignancie
  • Page 13 and 14: Current Clinical Controversies in M
  • Page 15 and 16: Stories We Tell One Another: Narrat
  • Page 17 and 18: TUMOR BIOLOGY Increasing the Reliab
  • Page 19 and 20: 2012-2013 Cancer Education Committe
  • Page 21 and 22: John Frederick De Groot, MD The Uni
  • Page 23 and 24: Robert J. Mayer, MD Dana-Farber Can
  • Page 25 and 26: Timothy Joseph Whelan, BM, BCh, MSc
  • Page 27 and 28: Lee Helman, MD National Cancer Inst
  • Page 29 and 30: 2013 Annual Meeting Supporters* MIS
  • Page 31 and 32: Letter from the Editor In my fırst
  • Page 33 and 34: Adjuvant Chemotherapy: Which Patien
  • Page 35 and 36: tion, or lymphovascular invasion wo
  • Page 37 and 38: should ideally be directed at bette
  • Page 39 and 40: Early and Late Long-Term Effects of
  • Page 41 and 42: CARDIAC DYSFUNCTION The most common
  • Page 43 and 44: References 1. Hassett MJ, Silver SM
  • Page 45 and 46: Translating Genomic Research into C
  • Page 47 and 48: TABLE 1. Glossary of Terms Commonly
  • Page 49 and 50: TABLE 2. Summary of Selected Next-G
  • Page 51 and 52: hypomethylated phenotype that overl
  • Page 53 and 54:

    17. Stephens PJ, McBride DJ, Lin ML

  • Page 55 and 56:

    ZARDAVAS ET AL Beyond Trastuzumab a

  • Page 57 and 58:

    ZARDAVAS ET AL TABLE 2. Selected On

  • Page 59 and 60:

    ZARDAVAS ET AL this study is the co

  • Page 61 and 62:

    ZARDAVAS ET AL reported from the ph

  • Page 63 and 64:

    ZARDAVAS ET AL positive breast canc

  • Page 65 and 66:

    BREAST CANCER Finding the Balance i

  • Page 67 and 68:

    PEREZ-GARCIA, MUÑOZ-COUSELO, AND C

  • Page 69 and 70:

    PEREZ-GARCIA, MUÑOZ-COUSELO, AND C

  • Page 71 and 72:

    PEREZ-GARCIA, MUÑOZ-COUSELO, AND C

  • Page 73 and 74:

    STRASSER-WEIPPL AND GOSS Competing

  • Page 75 and 76:

    STRASSER-WEIPPL AND GOSS dictive fo

  • Page 77 and 78:

    STRASSER-WEIPPL AND GOSS SPEAKING O

  • Page 79 and 80:

    STRASSER-WEIPPL AND GOSS 33. Liedtk

  • Page 81 and 82:

    JULIA WHITE Do We Need to Irradiate

  • Page 83 and 84:

    JULIA WHITE TABLE 1. “Low Risk”

  • Page 85 and 86:

    JULIA WHITE References 1. Fisher B,

  • Page 87 and 88:

    IYENGAR, HUDIS, AND DANNENBERG Obes

  • Page 89 and 90:

    IYENGAR, HUDIS, AND DANNENBERG FIG

  • Page 91 and 92:

    IYENGAR, HUDIS, AND DANNENBERG and

  • Page 93 and 94:

    LIGIBEL AND STRICKLER Obesity and I

  • Page 95 and 96:

    LIGIBEL AND STRICKLER nearly two-fo

  • Page 97 and 98:

    LIGIBEL AND STRICKLER TABLE 2. Sele

  • Page 99 and 100:

    LIGIBEL AND STRICKLER defıne the r

  • Page 101 and 102:

    BREAST CANCER Optimizing Locoregion

  • Page 103 and 104:

    HO AND CODY TABLE 1. Results of SLN

  • Page 105 and 106:

    HO AND CODY Looking further ahead,

  • Page 107 and 108:

    GROBMYER, COWHER, AND CROWE Optimiz

  • Page 109 and 110:

    GROBMYER, COWHER, AND CROWE associa

  • Page 111 and 112:

    GROBMYER, COWHER, AND CROWE mately

  • Page 113 and 114:

    BREAST CANCER Pushing the Limits of

  • Page 115 and 116:

    RASTOGI ET AL lowing AC increased t

  • Page 117 and 118:

    RASTOGI ET AL in the neoadjuvant se

  • Page 119 and 120:

    RASTOGI ET AL Disclosures of Potent

  • Page 121 and 122:

    BREAST CANCER Surveillance and Moni

  • Page 123 and 124:

    JOCHELSON, HAYES, AND GANZ without

  • Page 125 and 126:

    JOCHELSON, HAYES, AND GANZ chemothe

  • Page 127 and 128:

    JOCHELSON, HAYES, AND GANZ 3. Davie

  • Page 129 and 130:

    WILSON AND CHIA Treatment Algorithm

  • Page 131 and 132:

    WILSON AND CHIA TABLE 1. First-Line

  • Page 133 and 134:

    WILSON AND CHIA numerically the haz

  • Page 135 and 136:

    WILSON AND CHIA References 1. Nabho

  • Page 137 and 138:

    JOHNSTON AND SCHIAVON Treatment Alg

  • Page 139 and 140:

    JOHNSTON AND SCHIAVON TABLE 1. Rand

  • Page 141 and 142:

    JOHNSTON AND SCHIAVON TABLE 2. Rand

  • Page 143 and 144:

    JOHNSTON AND SCHIAVON events being

  • Page 145 and 146:

    JOHNSTON AND SCHIAVON tion of Akt/P

  • Page 147 and 148:

    TODD W. MILLER as clinically more i

  • Page 149 and 150:

    TODD W. MILLER than ER- cell lines.

  • Page 151 and 152:

    TODD W. MILLER anastrozole versus 5

  • Page 153 and 154:

    RAYMOND AND STOFFEL Familial Gastri

  • Page 155 and 156:

    RAYMOND AND STOFFEL TABLE 1. Heredi

  • Page 157 and 158:

    RAYMOND AND STOFFEL Peutz-Jeghers s

  • Page 159 and 160:

    Connecting Molecular Pathways to He

  • Page 161 and 162:

    BAP1 Function BAP1 is one of four U

  • Page 163 and 164:

    LFS develop gliomas, typically befo

  • Page 165 and 166:

    TABLE 2. Germline SDHx Mutations an

  • Page 167 and 168:

    13. Höiom V, Edsgärd D, Helgadott

  • Page 169 and 170:

    CANCER PREVENTION/EPIDEMIOLOGY Chem

  • Page 171 and 172:

    a nonsignifıcant increased risk of

  • Page 173 and 174:

    OTHER INDICATIONS/USES OF GTPs GTPs

  • Page 175 and 176:

    Marine-Derived Omega-3 Fatty Acids:

  • Page 177 and 178:

    compliance with dosing and little i

  • Page 179 and 180:

    22. Yee LD, Young DC, Rosol TJ, et

  • Page 181 and 182:

    (95% CI, 0.65-0.86) in Asian popula

  • Page 183 and 184:

    menopausal status will be needed as

  • Page 185 and 186:

    CANCER PREVENTION/EPIDEMIOLOGY High

  • Page 187 and 188:

    as BRCA germ-line mutations are exa

  • Page 189 and 190:

    FIG 1. IMPACT study design: Targete

  • Page 191 and 192:

    with predisposition to prostate can

  • Page 193 and 194:

    Mammographic Density and Risk of Br

  • Page 195 and 196:

    TABLE 1. Selected Characteristics o

  • Page 197 and 198:

    Prentice 25 [62] and further by Sch

  • Page 199 and 200:

    Mammographic Density: Intersection

  • Page 201 and 202:

    limits our ability to evaluate the

  • Page 203 and 204:

    FIG 3. Proposed algorithm for women

  • Page 205 and 206:

    east cancer risk and risk predictio

  • Page 207 and 208:

    MYRNA R. ROSENFELD Bridging Science

  • Page 209 and 210:

    MYRNA R. ROSENFELD TABLE 1. Clinica

  • Page 211 and 212:

    MYRNA R. ROSENFELD in clinical prac

  • Page 213 and 214:

    M. J. VAN DEN BENT How to Use Molec

  • Page 215 and 216:

    M. J. VAN DEN BENT PRACTICAL APPROA

  • Page 217 and 218:

    Antiangiogenic Therapy for Glioblas

  • Page 219 and 220:

    eduction in cerebral edema and spar

  • Page 221 and 222:

    overcome this invasive phenotype in

  • Page 223 and 224:

    more reliably assess underlying tum

  • Page 225 and 226:

    CLINICAL TRIALS Strategies to Overc

  • Page 227 and 228:

    selection of treatment in subgroups

  • Page 229 and 230:

    BACKGROUND Concerned with the incre

  • Page 231 and 232:

    centers, industry, and regulatory a

  • Page 233 and 234:

    References 1. Lander ES, Linton LM,

  • Page 235 and 236:

    PAUL B. CHAPMAN Mechanisms of Resis

  • Page 237 and 238:

    PAUL B. CHAPMAN analysis of melanom

  • Page 239 and 240:

    MCCASKILL-STEVENS ET AL The NCI Com

  • Page 241 and 242:

    MCCASKILL-STEVENS ET AL delivery re

  • Page 243 and 244:

    MCCASKILL-STEVENS ET AL structural

  • Page 245 and 246:

    DEVELOPMENTAL THERAPEUTICS Cancer a

  • Page 247 and 248:

    ANSELL AND VONDERHEIDE single subse

  • Page 249 and 250:

    ANSELL AND VONDERHEIDE pathogens wh

  • Page 251 and 252:

    ANSELL AND VONDERHEIDE 10. Baskar S

  • Page 253 and 254:

    DEVELOPMENTAL THERAPEUTICS Present

  • Page 255 and 256:

    HOWARD A. BURRIS III TABLE 1. Selec

  • Page 257 and 258:

    HOWARD A. BURRIS III 15. Thompson J

  • Page 259 and 260:

    MATHUR AND WEINER TABLE 1. ADCs in

  • Page 261 and 262:

    MATHUR AND WEINER Given that all ca

  • Page 263 and 264:

    LESLIE AND YOUNES Antibody-Drug Con

  • Page 265 and 266:

    LESLIE AND YOUNES TABLE 1. Antibody

  • Page 267 and 268:

    LESLIE AND YOUNES lymphocytes, is i

  • Page 269 and 270:

    DEVELOPMENTAL THERAPEUTICS Profile

  • Page 271 and 272:

    MUNOZ, SWANTON, AND KURZROCK method

  • Page 273 and 274:

    MUNOZ, SWANTON, AND KURZROCK of som

  • Page 275 and 276:

    MUNOZ, SWANTON, AND KURZROCK FIG 3.

  • Page 277 and 278:

    MUNOZ, SWANTON, AND KURZROCK Refere

  • Page 279 and 280:

    ABERNETHY ET AL The Ethics of Healt

  • Page 281 and 282:

    ABERNETHY ET AL Nonmaleficence (Avo

  • Page 283 and 284:

    ABERNETHY ET AL Aside from the prob

  • Page 285 and 286:

    ABERNETHY ET AL 9. Kim D, Schleiter

  • Page 287 and 288:

    DAVIS, BRUERA, AND MORGANSTERN Earl

  • Page 289 and 290:

    DAVIS, BRUERA, AND MORGANSTERN pall

  • Page 291 and 292:

    DAVIS, BRUERA, AND MORGANSTERN only

  • Page 293 and 294:

    DAVIS, BRUERA, AND MORGANSTERN onco

  • Page 295 and 296:

    ANTONELLA SURBONE Professionalism i

  • Page 297 and 298:

    ANTONELLA SURBONE use of current, b

  • Page 299 and 300:

    ANTONELLA SURBONE Professionalism r

  • Page 301 and 302:

    MATJAZ ZWITTER TABLE 1. Risk Factor

  • Page 303 and 304:

    MATJAZ ZWITTER For such patients, e

  • Page 305 and 306:

    GASTROINTESTINAL (COLORECTAL) CANCE

  • Page 307 and 308:

    SCOTT KOPETZ as the clinical benef

  • Page 309 and 310:

    SCOTT KOPETZ FIG 2. A) A histogram

  • Page 311 and 312:

    SCOTT KOPETZ previously treated wit

  • Page 313 and 314:

    VENOOK AND SALTZ exploratory series

  • Page 315 and 316:

    VENOOK AND SALTZ original 120-page

  • Page 317 and 318:

    HIRSCH AND SCHULMAN The Economics o

  • Page 319 and 320:

    HIRSCH AND SCHULMAN TARGET MARKET S

  • Page 321 and 322:

    HIRSCH AND SCHULMAN 6. Personalized

  • Page 323 and 324:

    Approach to the Older Patient with

  • Page 325 and 326:

    DETERMINING APPROPRIATE THERAPY IN

  • Page 327 and 328:

    ecurrence. In those with a lower ri

  • Page 329 and 330:

    Achieving Health Equity in Colorect

  • Page 331 and 332:

    FIG 2. Colorectal cancer screening

  • Page 333 and 334:

    also need to put further emphasis o

  • Page 335 and 336:

    Cancer of Unknown Primary Site: Imp

  • Page 337 and 338:

    FIG 1. Evaluation and management of

  • Page 339 and 340:

    A molecular profıle assay appears

  • Page 341 and 342:

    References 1. Greco FA, Hainsworth,

  • Page 343 and 344:

    PRESENTATION, IMAGING, AND DIAGNOSI

  • Page 345 and 346:

    TABLE 1. Select Results of CRS plus

  • Page 347 and 348:

    may be reasonable to assume similar

  • Page 349 and 350:

    Rare but Real: Management of Small

  • Page 351 and 352:

    adjuvant therapy in higher-risk pat

  • Page 353 and 354:

    pathogenesis of neoplasia in the sm

  • Page 355 and 356:

    PHILIP J. JOHNSON How Do Mechanisms

  • Page 357 and 358:

    PHILIP J. JOHNSON THE HEPATITIS C V

  • Page 359 and 360:

    PHILIP J. JOHNSON 24. Anastas JN, M

  • Page 361 and 362:

    KELLEY AND VENOOK TABLE 1. Adverse

  • Page 363 and 364:

    KELLEY AND VENOOK TABLE 3. Response

  • Page 365 and 366:

    KELLEY AND VENOOK randomized, doubl

  • Page 367 and 368:

    DANIEL COIT Surgical Approaches to

  • Page 369 and 370:

    DANIEL COIT wound infection (7.7% v

  • Page 371 and 372:

    DANIEL COIT quality-of-life indicat

  • Page 373 and 374:

    DANIEL COIT 15. Briez N, Piessen G,

  • Page 375 and 376:

    HAUSTERMANS TABLE 1. Overview of Ph

  • Page 377 and 378:

    HAUSTERMANS Disclosures of Potentia

  • Page 379 and 380:

    MANISH A. SHAH randomly assigned 44

  • Page 381 and 382:

    MANISH A. SHAH vival, demonstrating

  • Page 383 and 384:

    GENITOURINARY CANCER Castration-Res

  • Page 385 and 386:

    KARIM FIZAZI TABLE 1. A Proposed Ev

  • Page 387 and 388:

    KARIM FIZAZI phase II trial in 201

  • Page 389 and 390:

    GULLEY, MADAN, AND HEERY Therapeuti

  • Page 391 and 392:

    GULLEY, MADAN, AND HEERY anti-PD1 o

  • Page 393 and 394:

    GULLEY, MADAN, AND HEERY PSA-target

  • Page 395 and 396:

    Targeting Molecular Aberrations in

  • Page 397 and 398:

    TABLE 2. Selected Clinical Trials o

  • Page 399 and 400:

    19. Aftab DT, McDonald DM. MET and

  • Page 401 and 402:

    FIG 1. The United States trimodalit

  • Page 403 and 404:

    FIG 3. Patterns of recurrence after

  • Page 405 and 406:

    adiotherapy or cystectomy in Yorksh

  • Page 407 and 408:

    GENITOURINARY CANCER Renal Cell Car

  • Page 409 and 410:

    therapies may play a role. 9 PFS ha

  • Page 411 and 412:

    GENITOURINARY CANCER The Role of An

  • Page 413 and 414:

    a PSA level of 10 or higher, and su

  • Page 415 and 416:

    TABLE 2. Features of Hypogonadism v

  • Page 417 and 418:

    delaying development of castration

  • Page 419 and 420:

    androgen suppression on androgen-de

  • Page 421 and 422:

    KLEPIN ET AL Individualizing Treatm

  • Page 423 and 424:

    KLEPIN ET AL and 29%) and OS (45, 3

  • Page 425 and 426:

    KLEPIN ET AL functional/cognitive s

  • Page 427 and 428:

    KLEPIN ET AL Reducing bortezomib sc

  • Page 429 and 430:

    KLEPIN ET AL TABLE 3. Studies Focus

  • Page 431 and 432:

    KLEPIN ET AL patients with acute my

  • Page 433 and 434:

    GERIATRIC ONCOLOGY Is Age Just a Nu

  • Page 435 and 436:

    AJEET GAJRA TABLE 1. Summary of Adj

  • Page 437 and 438:

    AJEET GAJRA GERIATRIC ASSESSMENT Ch

  • Page 439 and 440:

    WU AND GOLDBERG Managing Choices fo

  • Page 441 and 442:

    WU AND GOLDBERG 4 years was 4.7% wo

  • Page 443 and 444:

    GYNECOLOGIC CANCER Ovarian Cancer:

  • Page 445 and 446:

    DAVID M. GERSHENSON ovary, no unive

  • Page 447 and 448:

    DAVID M. GERSHENSON TABLE 1. Studie

  • Page 449 and 450:

    JAIN AND SEIDEN Rare Epithelial Tum

  • Page 451 and 452:

    JAIN AND SEIDEN TABLE 1. Comparison

  • Page 453 and 454:

    JAIN AND SEIDEN 22. Anglesio MS, Ge

  • Page 455 and 456:

    G. THOMAS rates to conventional che

  • Page 457 and 458:

    G. THOMAS with the advent of confor

  • Page 459 and 460:

    MATEI, BROWN, AND FRAZIER Updates i

  • Page 461 and 462:

    MATEI, BROWN, AND FRAZIER require c

  • Page 463 and 464:

    MATEI, BROWN, AND FRAZIER carcinoma

  • Page 465 and 466:

    MATEI, BROWN, AND FRAZIER 47. Nicho

  • Page 467 and 468:

    SALVESEN, WERNER, AND KRAKSTAD PI3K

  • Page 469 and 470:

    SALVESEN, WERNER, AND KRAKSTAD TABL

  • Page 471 and 472:

    PENELOPE M. WEBB Obesity and Gyneco

  • Page 473 and 474:

    PENELOPE M. WEBB TABLE 1. Relative

  • Page 475 and 476:

    PENELOPE M. WEBB was associated wit

  • Page 477 and 478:

    PENELOPE M. WEBB References 1. Finu

  • Page 479 and 480:

    Pathologic Diagnosis, Origin, and N

  • Page 481 and 482:

    symptoms mimicking acute appendicit

  • Page 483 and 484:

    Classifıcation of Tumours of the D

  • Page 485 and 486:

    Treatment and Trials: Ovarian Cance

  • Page 487 and 488:

    e offered an alternative pathway, s

  • Page 489 and 490:

    aseline, and FIGO stage IV. The use

  • Page 491 and 492:

    severe toxicity from chemotherapy a

  • Page 493 and 494:

    48. Bukowski RM, Ozols RF, Markman

  • Page 495 and 496:

    Locally Advanced Head and Neck Canc

  • Page 497 and 498:

    followed by concurrent CRT to theor

  • Page 499 and 500:

    have also shown clinical benefıt i

  • Page 501 and 502:

    investigation is required to determ

  • Page 503 and 504:

    HEAD AND NECK CANCER Molecular Path

  • Page 505 and 506:

    adenosine-triphosphate competitive

  • Page 507 and 508:

    signaling in maintenance of the res

  • Page 509 and 510:

    Fig 2. Overview of Class 1 PI3K sig

  • Page 511 and 512:

    Based on preclinical data using an

  • Page 513 and 514:

    dependence through epithelial-to-me

  • Page 515 and 516:

    Salivary Gland Cancer: An Update on

  • Page 517 and 518:

    signaling pathway is a novel molecu

  • Page 519 and 520:

    Patients with ACC treated with radi

  • Page 521 and 522:

    inactivation of Apc and Pten in the

  • Page 523 and 524:

    SINGER, LANGENDIJK, AND YAROM Asses

  • Page 525 and 526:

    SINGER, LANGENDIJK, AND YAROM Secon

  • Page 527 and 528:

    SINGER, LANGENDIJK, AND YAROM Predi

  • Page 529 and 530:

    STEPHEN T. SONIS Oral Mucositis in

  • Page 531 and 532:

    STEPHEN T. SONIS BIOLOGIC EVENTS TH

  • Page 533 and 534:

    STEPHEN T. SONIS randomised trial w

  • Page 535 and 536:

    DAVID KHAYAT National Cancer Plans:

  • Page 537 and 538:

    DAVID KHAYAT Disclosures of Potenti

  • Page 539 and 540:

    CARLOS VALLEJOS In 1985, INEN was d

  • Page 541 and 542:

    CARLOS VALLEJOS 62,979 patients cov

  • Page 543 and 544:

    Difficult to Swallow: Issues Affect

  • Page 545 and 546:

    setting, sometimes in the absence o

  • Page 547 and 548:

    Individual economic situations shou

  • Page 549 and 550:

    Disparities and Challenges in Adher

  • Page 551 and 552:

    greater than 80%. MPR is defıned a

  • Page 553 and 554:

    discontinue hormone therapy. Black

  • Page 555 and 556:

    HEALTH SERVICES RESEARCH Reducing I

  • Page 557 and 558:

    prostate screening tests. Findings

  • Page 559 and 560:

    Although opponents to such plans fo

  • Page 561 and 562:

    HEALTH SERVICES RESEARCH The Cuttin

  • Page 563 and 564:

    three times higher likelihood of ac

  • Page 565 and 566:

    TABLE 1. Examples of Structure of S

  • Page 567 and 568:

    surgeon performance, and operating

  • Page 569 and 570:

    BEJAR ET AL Myelodysplastic Syndrom

  • Page 571 and 572:

    BEJAR ET AL FIG 2. Comparison of th

  • Page 573 and 574:

    BEJAR ET AL TABLE 1. Diagnostic Cri

  • Page 575 and 576:

    BEJAR ET AL hand, accounted for jus

  • Page 577 and 578:

    BEJAR ET AL TABLE 2. Results of Pha

  • Page 579 and 580:

    BEJAR ET AL FIG 4. Current algorith

  • Page 581 and 582:

    BEJAR ET AL 4. Greenberg PL, Tuechl

  • Page 583 and 584:

    BEJAR ET AL Tosedostat, an inhibito

  • Page 585 and 586:

    Biology and Treatment of Acute Lymp

  • Page 587 and 588:

    TABLE 2. Clinical Trials Evaluating

  • Page 589 and 590:

    16. Nachman JB, La MK, Hunger SP, e

  • Page 591 and 592:

    FIG 1. Practical approach for treat

  • Page 593 and 594:

    References 1. Bassan R, Hoelzer D.

  • Page 595 and 596:

    47% and 57% in those who did not re

  • Page 597 and 598:

    schedule was selected as it appeare

  • Page 599 and 600:

    acute lymphocytic leukaemia: a phas

  • Page 601 and 602:

    The Role of JAK1/2 Inhibitors in th

  • Page 603 and 604:

    MF. The results of these trials hav

  • Page 605 and 606:

    Disclosures of Potential Conflicts

  • Page 607 and 608:

    FIG 1. Mechanisms of resistance in

  • Page 609 and 610:

    3-month transcript levels to be pre

  • Page 611 and 612:

    Disclosures of Potential Conflicts

  • Page 613 and 614:

    The Role of Kinase Inhibitors in th

  • Page 615 and 616:

    studies reported no responses in pa

  • Page 617 and 618:

    Disclosures of Potential Conflicts

  • Page 619 and 620:

    LUNG CANCER Beyond Progression: Tre

  • Page 621 and 622:

    HETEROGENEITY OF PRESENTATIONS WITH

  • Page 623 and 624:

    The increased complexity of resista

  • Page 625 and 626:

    the recommendation for fırst-line

  • Page 627 and 628:

    LUNG CANCER Current Clinical Contro

  • Page 629 and 630:

    TABLE 1. Trials of Preoperative Che

  • Page 631 and 632:

    the surgical resection. Third, preo

  • Page 633 and 634:

    29. Martins RG. Treatment of Locall

  • Page 635 and 636:

    LAURA QM CHOW Exploring Novel Immun

  • Page 637 and 638:

    LAURA QM CHOW March 2011 as a singl

  • Page 639 and 640:

    LAURA QM CHOW Immune-Mediated Pneum

  • Page 641 and 642:

    LAURA QM CHOW References 1. Dasanu

  • Page 643 and 644:

    MORSE ET AL IMMUNE BIOMARKERS Becau

  • Page 645 and 646:

    MORSE ET AL immunizations, it is po

  • Page 647 and 648:

    MORSE ET AL References 1. Biomarker

  • Page 649 and 650:

    LUNG CANCER Lung Cancer in 2013: A

  • Page 651 and 652:

    CARLOS GIL FERREIRA FIG 1. GLOBOCAN

  • Page 653 and 654:

    CARLOS GIL FERREIRA FIG 2. Working

  • Page 655 and 656:

    NOWAK, CALVO, AND SORIA Europe Does

  • Page 657 and 658:

    NOWAK, CALVO, AND SORIA FIG. 1. The

  • Page 659 and 660:

    NOWAK, CALVO, AND SORIA focus has b

  • Page 661 and 662:

    LUNG CANCER Lung Cancer in 2013: St

  • Page 663 and 664:

    SHEPHERD, BUNN, AND PAZ-ARES fılte

  • Page 665 and 666:

    SHEPHERD, BUNN, AND PAZ-ARES TABLE

  • Page 667 and 668:

    SHEPHERD, BUNN, AND PAZ-ARES the PA

  • Page 669 and 670:

    SHEPHERD, BUNN, AND PAZ-ARES (G-Cb)

  • Page 671 and 672:

    MORGENSZTERN, DEVARAKONDA, AND GOVI

  • Page 673 and 674:

    MORGENSZTERN, DEVARAKONDA, AND GOVI

  • Page 675 and 676:

    MORGENSZTERN, DEVARAKONDA, AND GOVI

  • Page 677 and 678:

    SCAGLIOTTI ET AL Current State-of-t

  • Page 679 and 680:

    SCAGLIOTTI ET AL sb-PC (33% vs. 25%

  • Page 681 and 682:

    SCAGLIOTTI ET AL References 1. Worl

  • Page 683 and 684:

    WARREN AND CUMMINGS FIG 1. Timeline

  • Page 685 and 686:

    WARREN AND CUMMINGS treatment, perh

  • Page 687 and 688:

    WARREN AND CUMMINGS 20. Warren GW,

  • Page 689 and 690:

    Aberrant Epigenetic Regulation: A C

  • Page 691 and 692:

    FIG 1. Methylation and chromatin pa

  • Page 693 and 694:

    Epigenetic Therapy As a Primer for

  • Page 695 and 696:

    LYMPHOMA AND PLASMA CELL DISORDERS

  • Page 697 and 698:

    cell lines and has been shown to in

  • Page 699 and 700:

    TABLE 1. Selected List of Clinical

  • Page 701 and 702:

    Further work is needed now to not o

  • Page 703 and 704:

    LYMPHOMA AND PLASMA CELL DISORDERS

  • Page 705 and 706:

    Myeloma Working Group (IMWG) criter

  • Page 707 and 708:

    could continue with 6-week cycles b

  • Page 709 and 710:

    Update on the Initial Therapy of Mu

  • Page 711 and 712:

    TABLE 2. Summary of Post-ASCT Outco

  • Page 713 and 714:

    thalidomide HD dex. However, this

  • Page 715 and 716:

    New Tools for Diagnosis and Monitor

  • Page 717 and 718:

    MM and other plasma cell dyscrasias

  • Page 719 and 720:

    normal, focal, variegated, or diffu

  • Page 721 and 722:

    LYMPHOMA AND PLASMA CELL DISORDERS

  • Page 723 and 724:

    The transition from extended fıeld

  • Page 725 and 726:

    ABVD. Sixty-nine of 196 (35%) patie

  • Page 727 and 728:

    least modest exposure to the heart,

  • Page 729 and 730:

    MELANOMA/SKIN CANCERS Evidence-Base

  • Page 731 and 732:

    However, despite these apparent adv

  • Page 733 and 734:

    include routine histopathology as o

  • Page 735 and 736:

    intraoperative lymphatic mapping an

  • Page 737 and 738:

    FRANCIS ET AL Surveillance Options

  • Page 739 and 740:

    FRANCIS ET AL TABLE 1. Modalities f

  • Page 741 and 742:

    FRANCIS ET AL in recent years and i

  • Page 743 and 744:

    J. WILLIAM HARBOUR Genomic, Prognos

  • Page 745 and 746:

    J. WILLIAM HARBOUR CONCLUSION With

  • Page 747 and 748:

    MELANOMA Multidisciplinary Approach

  • Page 749 and 750:

    LONG AND MARGOLIN dacarbazine. 15 S

  • Page 751 and 752:

    LONG AND MARGOLIN Most importantly,

  • Page 753 and 754:

    LONG AND MARGOLIN 14. Jacquillat C,

  • Page 755 and 756:

    RAMAKRISHNA AND MARGOLIN selection

  • Page 757 and 758:

    RAMAKRISHNA AND MARGOLIN control wi

  • Page 759 and 760:

    PATIENT AND SURVIVOR CARE Beyond th

  • Page 761 and 762:

    TERESA GILEWSKI of the same issues

  • Page 763 and 764:

    TERESA GILEWSKI References 1. Frank

  • Page 765 and 766:

    DAVID P. STEENSMA treasures such as

  • Page 767 and 768:

    DAVID P. STEENSMA uncomfortable, fa

  • Page 769 and 770:

    PATIENT AND SURVIVOR CARE Global In

  • Page 771 and 772:

    EL SAGHIR, ASSI, AND PYLE with canc

  • Page 773 and 774:

    EL SAGHIR, ASSI, AND PYLE and invol

  • Page 775 and 776:

    EL SAGHIR, ASSI, AND PYLE Reference

  • Page 777 and 778:

    LICHTMAN developing countries to ex

  • Page 779 and 780:

    PATIENT AND SURVIVOR CARE Thrombosi

  • Page 781 and 782:

    LYMAN, KHORANA, AND FALANGA FIG 1.

  • Page 783 and 784:

    LYMAN, KHORANA, AND FALANGA TABLE 1

  • Page 785 and 786:

    LYMAN, KHORANA, AND FALANGA laparot

  • Page 787 and 788:

    LYMAN, KHORANA, AND FALANGA Referen

  • Page 789 and 790:

    PEDIATRIC ONCOLOGY Immunotherapy fo

  • Page 791 and 792:

    LABELLE AND CUNNINGHAM The purpose

  • Page 793 and 794:

    LABELLE AND CUNNINGHAM Evidence for

  • Page 795 and 796:

    LABELLE AND CUNNINGHAM 33. Locatell

  • Page 797 and 798:

    DAW AND MAHAJAN Photons or Protons

  • Page 799 and 800:

    DAW AND MAHAJAN the United States w

  • Page 801 and 802:

    DAW AND MAHAJAN facilities and the

  • Page 803 and 804:

    PEDIATRIC CANCER What’s New and I

  • Page 805 and 806:

    CAROLA A. S. ARNDT TABLE 1. Staging

  • Page 807 and 808:

    CAROLA A. S. ARNDT intermediate-ris

  • Page 809 and 810:

    FERGUSON, HINGORANI, AND GUPTA Emer

  • Page 811 and 812:

    FERGUSON, HINGORANI, AND GUPTA TABL

  • Page 813 and 814:

    FERGUSON, HINGORANI, AND GUPTA 28.

  • Page 815 and 816:

    ERIN R. RUDZINSKI histologic patter

  • Page 817 and 818:

    ERIN R. RUDZINSKI incorporation of

  • Page 819 and 820:

    SLEDGE, MILLER, AND HAUSER CancerLi

  • Page 821 and 822:

    SLEDGE, MILLER, AND HAUSER THE CANC

  • Page 823 and 824:

    SLEDGE, MILLER, AND HAUSER supplied

  • Page 825 and 826:

    Understanding and Surviving the Tra

  • Page 827 and 828:

    care. Consultants in Medical Oncolo

  • Page 829 and 830:

    on chemotherapy costs, which accoun

  • Page 831 and 832:

    8. Applying the cancer cost savings

  • Page 833 and 834:

    PRACTICE MANAGEMENT AND INFORMATION

  • Page 835 and 836:

    the “home medications” section

  • Page 837 and 838:

    U.S. medical claims. Even before th

  • Page 839 and 840:

    PATEL AND TRAN Opportunities for On

  • Page 841 and 842:

    PATEL AND TRAN declared as Essentia

  • Page 843 and 844:

    PATEL AND TRAN Disclosures of Poten

  • Page 845 and 846:

    DIZON, POLITI, AND BACK, MD The Pow

  • Page 847 and 848:

    DIZON, POLITI, AND BACK, MD (X out

  • Page 849 and 850:

    DIZON, POLITI, AND BACK, MD and sha

  • Page 851 and 852:

    The Advanced Practice Professionals

  • Page 853 and 854:

    Efficient and Effective Models for

  • Page 855 and 856:

    TABLE 2. Models of Care 1. Shared C

  • Page 857 and 858:

    REEDER-HAYES Women in Oncology: Pro

  • Page 859 and 860:

    REEDER-HAYES funding for research c

  • Page 861 and 862:

    REEDER-HAYES which I codirect to ma

  • Page 863 and 864:

    REEDER-HAYES Mentoring Truths Choos

  • Page 865 and 866:

    SARCOMA Systemic Therapy in Sarcoma

  • Page 867 and 868:

    BLAY, DERBEL, AND RAY-COQUARD trial

  • Page 869 and 870:

    BLAY, DERBEL, AND RAY-COQUARD • P

  • Page 871 and 872:

    RYAN AND DESAI The Past, Present, a

  • Page 873 and 874:

    RYAN AND DESAI doxorubicin and ifos

  • Page 875 and 876:

    RYAN AND DESAI authorities for the

  • Page 877 and 878:

    RYAN AND DESAI alone in patients wi

  • Page 879 and 880:

    SARCOMA The Use of Local Modalities

  • Page 881 and 882:

    HOHENBERGER, KASPER, AND AHRAR may

  • Page 883 and 884:

    HOHENBERGER, KASPER, AND AHRAR four

  • Page 885 and 886:

    HOHENBERGER, KASPER, AND AHRAR bene

  • Page 887 and 888:

    HOHENBERGER, KASPER, AND AHRAR 14.

  • Page 889 and 890:

    C. GLENN BEGLEY An Unappreciated Ch

  • Page 891 and 892:

    C. GLENN BEGLEY CONCLUSION We have

  • Page 893 and 894:

    LOONG AND SIU drug, identify pharma

  • Page 895 and 896:

    LOONG AND SIU may be considered int

  • Page 897 and 898:

    TUMOR BIOLOGY Targeting the PI3K-Ak

  • Page 899 and 900:

    OWONIKOKO AND KHURI combination of

  • Page 901 and 902:

    OWONIKOKO AND KHURI TABLE 2. Inhibi

  • Page 903 and 904:

    OWONIKOKO AND KHURI of hypertension

  • Page 905:

    This publication is supported by an

ASCO Annual Meeting 2008 - Actavis
actavis
ASCO Annual Meeting 2008 - Actavis
actavis
2012 EDUCATIONAL BOOK - American Society of Clinical Oncology
asco.org
exhibitor policies & information - ASCO Annual Meeting - American ...
chicago2013.asco.org
Annual Meeting Program Book - American Phytopathological Society
apsnet.org
Annual Meeting Proceedings Part 1 - American Society of Clinical ...
asco.org
2010 ASABE Annual International Meeting - American Society of ...
asabe.org
71st Annual Meeting of the American Society of Brewing Chemists
meeting.asbcnet.org
Annual International Meeting - American Society of Agricultural and ...
asabe.org
The 63rd Annual Meeting - American Society of Criminology
asc41.com
Annual Meeting Preliminary Program - Society of Toxicology
toxicology.org
Annual Meeting - American Neurological Association
aneuroa.org
annual meeting submissions deadline - Society for American ...
saa.org
annual meeting - American Orthopaedic Society for Sports Medicine
sportsmed.org
2007 ABA Annual Meeting Program Book - American Bar Association
americanbar.org
Abstract Book 2011 - CIMT Annual Meeting 2013
meeting.cimt.eu
49th AnnuAl Meeting - Society for Surgery of the Alimentary Tract
ssat.com
47th AnnuAl Meeting - Society for Surgery of the Alimentary Tract
ssat.com
50th AnnuAl Meeting - Society for Surgery of the Alimentary Tract
ssat.com
ASER 20th Annual Scientific Meeting Brochure - American Society ...
erad.org
Annual Meeting Program and Abstract Book - The American Schools ...
asor.org
2010 iSBTc Annual Meeting - Society for Immunotherapy of Cancer
sitcancer.org
15th Annual Scientific Meeting - Heart Failure Society of America
hfsa.org
ACAAI 2010 Annual Meeting Program Guide - American College of ...
acaai.org
22nd Annual Meeting and Symposium - American Academy of ...
aaap.org
55th Annual Meeting of the Italian Cancer Society - Centro ...
ercongressi.it
annUaL Meeting - American Orthopaedic Society for Sports Medicine
sportsmed.org
16th Annual Scientific Meeting - Heart Failure Society of America
hfsa.org
23rd Annual Meeting - Society for Immunotherapy of Cancer
sitcancer.org
Annual Meeting Swiss Society of Neonatology
neonet.ch